In chronic hepatitis C, end-of-treatment biochemical response was higher with thymosin alpha1 plus interferon (37.1%) than with interferon alone (16.2%).
In plain wordsIn people with chronic hepatitis C, thymosin alpha1 plus interferon gave more normal liver enzymes at treatment end than interferon alone (37.1% versus 16.2%).
- Peptide
- Thymosin alpha-1
- Outcome
- IncreaseEnd-of-treatment biochemical response
- Study
n = 109
- Comparator
- Interferon alone
- Outcome group
- Liver fat and liver function · Liver
- Studied dose
- 1.6 mg twice weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
- End-of-treatment biochemical response
- 37.1%
- IFN/TA1
- End-of-treatment biochemical response
- 16.2%
- IFN alone
Source sentences
End-of-treatment biochemical response was seen in 37.1% of patients treated with combination therapy, 16.2% of patients treated with IFN alone, and 2.7% of untreated controls by intent-to-treat analysis (IFN/TA1 vs. IFN, chi2 = 4.05, P = .04).
2 context sentences(design, population, supporting numbers)
We performed a randomized, double-blind, placebo-controlled trial to compare the biological activity of a combination TA1 and IFN with that seen for IFN alone in patients with chronic hepatitis C infection.
One hundred nine patients were randomized for intention to treat and received 1.6 mg of TA1 subcutaneously twice weekly and 3 MU of IFN three times weekly; 3 MU of IFN three times weekly and placebo TA1; or placebo for both agents.